cisplatin,methotrexate,carboplatin,doxorubicin,gemcitabine,pembrolizumab,atezolizumab
merck,roche
['muc ,(-much)', 'methotrexate', 'pembro', 'atezo', 'cisplatin', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'carboplatin', 'doxorubicin', 'gemcitabine']
for those (like me) having trouble keeping up with the timeline of fda movement in the 1l muc setting for cpis, great summary from in #gu23 discussion 4/21: atezo keeps indication 8/21: remove pembro indication for cis-ineligible pd-l1 ; cont for 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday